Roivant Sciences Ltd.
ROIV
$28.58
-$0.95-3.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.06% | 27.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.06% | 27.24% | |||
| Cost of Revenue | 19.98% | 1.16% | |||
| Gross Profit | -19.91% | -0.91% | |||
| SG&A Expenses | -1.14% | 35.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.15% | 16.15% | |||
| Operating Income | -9.05% | -16.09% | |||
| Income Before Tax | 256.39% | -82.57% | |||
| Income Tax Expenses | 321.54% | 233.55% | |||
| Earnings from Continuing Operations | 213.40% | -88.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -210.33% | -8.97% | |||
| Net Income | 213.95% | -134.23% | |||
| EBIT | -9.05% | -16.09% | |||
| EBITDA | -9.08% | -16.22% | |||
| EPS Basic | 213.08% | -128.91% | |||
| Normalized Basic EPS | -68.80% | -21.45% | |||
| EPS Diluted | 173.38% | -124.47% | |||
| Normalized Diluted EPS | -45.88% | -21.45% | |||
| Average Basic Shares Outstanding | 0.76% | 2.34% | |||
| Average Diluted Shares Outstanding | 16.56% | 2.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||